ARCHIVES

Carfilzomib Demonstrates Clinical Benefit Rate of 64%

This article is from The Cancer Letter archive.

Vol. 34 No. 12 | December 30, 2011

Download PDF Visit The Full Archive

Related Articles

Final Issue Of Decade; Office Closed, But Not Phone Or Fax

December 15, 1989

AIDS Biological Specimens Available From NIH

November 22, 1985

Deborah Mayer Appointed To NCAB; Cancer Panel Plans Meetings For July 9

May 10, 1991

Novartis Submits Gleevec Data To FDA Seeking Approval For Use In GI Tumors.

October 26, 2001

Carbone to Give Up ECOG Chairmanship; DCE’s Adamson Receives Presidential Executive Award

October 6, 1989

Conversation with The Cancer Letter: Kazerooni: The Case for Broad Coverage

March 21, 2014